ビバリルジンの市場：剤形、用途、最終用途別-2024-2030年の世界予測

ビバリルジン市場規模は2023年に12億3,000万米ドルと推計され、2024年には13億1,000万米ドルに達し、CAGR 6.13%で2030年には18億7,000万米ドルに達すると予測されます。

ビバリルジンは主に抗凝固薬として使用される医薬品で、血栓の形成を防ぐのに役立ちます。ビバリルジンは直接トロンビン阻害薬として知られる薬剤のクラスに属し、血管内で血栓が形成される可能性を低減します。これは、血栓が心臓発作、脳卒中、動脈や静脈の閉塞などの深刻な健康問題につながる可能性がある状況では特に重要です。心臓病の世界の増加により、ビバリルジンが重要な役割を果たす血管形成術を含む効果的な治療法の必要性が高まっています。さらに、ビバリルジンの有効性を高め、副作用を軽減するための製剤革新の大きな可能性が、より効果的で安全な抗凝固薬の選択肢をもたらしました。しかし、ビバリルジンは高価であり、また関連する医療処置が必要であるため、より幅広い患者層への利用が制限されています。さらに、代替抗凝固薬や市場に参入する新薬の存在が、エンドユーザーにおけるビバリルジン採用の課題となるかもしれないです。とはいえ、ヘルスケアのインフラ投資と支出の増加、心血管疾患の負担の増加により、先進的な薬剤の採用が進んでいます。ビバリルジンと他の薬剤との組み合わせの研究が進んでいることから、今後数年のうちに新たな治療領域が開拓され、ビバリルジンの用途が拡大することが期待されます。

投与形態：ビバリルジンの注射剤は外科手術の際に多く使用される

ビバリルジンの注射剤は、主に外科手術中や病院内などの急性期に使用され、即効的な抗凝固効果をもたらします。注射剤は迅速な作用発現が可能であり、突発的でリスクの高い凝固状態には極めて重要です。粉末のビバリルジンは投与に柔軟性があり、プレミックス液に比べて保存期間が長いため、しばしば好まれます。この剤形は、緊急性が低い場合や、患者個々のニーズに合わせて投与量を正確に調整する必要のある、オーダーメイドの投与レジメンに有利です。注射剤は、特にクリティカルケアや外科手術の現場において、緊急性と即時使用の利便性において比類のないものです。一方、粉末製剤は、使用直前に薬剤を調製し、特定の投与量のニーズに対応し、無駄を省くことができる汎用性と経済性を備えています。

最終用途：外来手術センターにおけるビバリルジンの新たな使用例

外来手術センター（ASC）は、宿泊を必要としない小手術にますます好まれるようになってきています。ASCでのビバリルジンの使用は、主にその最小限のモニタリング要件、迅速な作用、外来患者設定に適している半減期の短さを中心に展開されています。病院とクリニックは、急性期医療現場での幅広い用途から、ビバリルジンの主要なユーザーです。病院やクリニックでは、ビバリルジンをより広範で侵襲的な心血管系の処置に使用し、その迅速な発現と可逆性が非常に有益です。専門クリニック、特に循環器科では、診断用心臓カテーテル治療やその他の非外科的介入を受ける患者にビバリルジンを使用することが多いです。

地域的洞察

心臓病の有病率が高く、ヘルスケアインフラが発達しているため、南北アメリカではビバリルジンのニーズが高まっています。顧客の購買行動は、臨床的に証明された薬剤への信頼に傾いており、ビバリルジンは出血性合併症の軽減に効果的であることから好まれています。欧州諸国では、ビバリルジンに対する統一されたアプローチを示しており、これは欧州連合（EU）の規制やヘルスケアガイドラインの影響を大きく受けています。各国のヘルスケアシステム、利用可能性、償還政策によって採用は異なります。欧州連合（EU）では、高齢化社会の進展と心血管疾患の増加により、ビバリルジンに対するニーズが着実に高まっています。中東・アフリカでは、ヘルスケアへの投資の増加や国際的な医療機関との連携により、ビバリルジン市場が立ち上がりつつあります。アジア太平洋地域は、政府のヘルスケア改革推進と病院インフラへの投資により、ビバリルジンのダイナミックな市場となっています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスはビバリルジン市場の評価において極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、ビバリルジン市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力について徹底的な評価を行います。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.ビバリルジン市場の市場規模および予測は？

2.ビバリルジン市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.ビバリルジン市場の技術動向と規制枠組みは？

4.ビバリルジン市場における主要ベンダーの市場シェアは？

5.ビバリルジン市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 心血管疾患の治療に効果的な抗凝固剤の必要性が高まっている
    • 医薬品や医薬品の改善に対する消費者支出の増加
  • 抑制要因
    • ビバリルジンは他の選択肢に比べて高価である
  • 機会
    • すぐに使えるビバリルジン配合剤の開発
    • 新製品に対する政府承認の継続
  • 課題
    • ビバリルジンの使用に伴うリスクと複雑さ
• 市場セグメンテーション分析
  • 剤形：外科手術中に注射剤の形でビバリルジンを多用する
  • 最終用途：外来手術センターにおけるビバリルジンの新たな用途
• 市場ディスラプション分析
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 価格分析
• 技術分析
• 特許分析
• 貿易分析
• 規制枠組みの分析

第6章 ビバリルジンの市場剤形別

• 注射
• 粉

第7章 ビバリルジンの市場：用途別

• 血管形成術
• ヘパリン誘発性血小板減少症
• 経皮的冠動脈インターベンション

第8章 ビバリルジンの市場：最終用途別

• 外来手術センター
• 病院・クリニック
• 専門クリニック

第9章 南北アメリカのビバリルジンの市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のビバリルジンの市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのビバリルジンの市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • アベナシーがジェネリックビバリルジン注射剤を導入、米国での抗凝固薬の選択肢を拡大
  • エンドインターナショナル、臨床効率を高めるすぐに使えるビバリルジン注射剤を発売
  • エンドインターナショナル、米国すぐに使用できるビバリルジン注射剤の流通に関する戦略的提携を発表
• 戦略分析と提言

第13章 競争力のあるポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. BIVALIRUDIN MARKET RESEARCH PROCESS
• FIGURE 2. BIVALIRUDIN MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL BIVALIRUDIN MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL BIVALIRUDIN MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL BIVALIRUDIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. BIVALIRUDIN MARKET DYNAMICS
• FIGURE 7. GLOBAL BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL BIVALIRUDIN MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL BIVALIRUDIN MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. AMERICAS BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 14. AMERICAS BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. UNITED STATES BIVALIRUDIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 16. UNITED STATES BIVALIRUDIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 18. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. BIVALIRUDIN MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 22. BIVALIRUDIN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. BIVALIRUDIN MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL BIVALIRUDIN MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL BIVALIRUDIN MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL BIVALIRUDIN MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL BIVALIRUDIN MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL BIVALIRUDIN MARKET SIZE, BY INJECTION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL BIVALIRUDIN MARKET SIZE, BY INJECTION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL BIVALIRUDIN MARKET SIZE, BY POWDER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL BIVALIRUDIN MARKET SIZE, BY POWDER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL BIVALIRUDIN MARKET SIZE, BY ANGIOPLASTY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL BIVALIRUDIN MARKET SIZE, BY ANGIOPLASTY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL BIVALIRUDIN MARKET SIZE, BY HEPARIN-INDUCED THROMBOCYTOPENIA, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL BIVALIRUDIN MARKET SIZE, BY HEPARIN-INDUCED THROMBOCYTOPENIA, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL BIVALIRUDIN MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL BIVALIRUDIN MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL BIVALIRUDIN MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL BIVALIRUDIN MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 29. AMERICAS BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 30. AMERICAS BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 31. AMERICAS BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 32. AMERICAS BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 33. AMERICAS BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 34. AMERICAS BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 35. AMERICAS BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 36. AMERICAS BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 37. ARGENTINA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 38. ARGENTINA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 39. ARGENTINA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 40. ARGENTINA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 41. ARGENTINA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 42. ARGENTINA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 43. BRAZIL BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 44. BRAZIL BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 45. BRAZIL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 46. BRAZIL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 47. BRAZIL BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 48. BRAZIL BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 49. CANADA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 50. CANADA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 51. CANADA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 52. CANADA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 53. CANADA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 54. CANADA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 55. MEXICO BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 56. MEXICO BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 57. MEXICO BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 58. MEXICO BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 59. MEXICO BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 60. MEXICO BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 61. UNITED STATES BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 62. UNITED STATES BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 63. UNITED STATES BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 64. UNITED STATES BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 65. UNITED STATES BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 66. UNITED STATES BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 67. UNITED STATES BIVALIRUDIN MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 68. UNITED STATES BIVALIRUDIN MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 69. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 70. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 71. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 72. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 73. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 74. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 75. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 76. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 77. AUSTRALIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 78. AUSTRALIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 79. AUSTRALIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 80. AUSTRALIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 81. AUSTRALIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 82. AUSTRALIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 83. CHINA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 84. CHINA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 85. CHINA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 86. CHINA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 87. CHINA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 88. CHINA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 89. INDIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 90. INDIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 91. INDIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 92. INDIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 93. INDIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 94. INDIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 95. INDONESIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 96. INDONESIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 97. INDONESIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 98. INDONESIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 99. INDONESIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 100. INDONESIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 101. JAPAN BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 102. JAPAN BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 103. JAPAN BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 104. JAPAN BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 105. JAPAN BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 106. JAPAN BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 107. MALAYSIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 108. MALAYSIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 109. MALAYSIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 110. MALAYSIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 111. MALAYSIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 112. MALAYSIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 113. PHILIPPINES BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 114. PHILIPPINES BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 115. PHILIPPINES BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 116. PHILIPPINES BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 117. PHILIPPINES BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 118. PHILIPPINES BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 119. SINGAPORE BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 120. SINGAPORE BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 121. SINGAPORE BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 122. SINGAPORE BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 123. SINGAPORE BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 124. SINGAPORE BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 125. SOUTH KOREA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 126. SOUTH KOREA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 127. SOUTH KOREA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 128. SOUTH KOREA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 129. SOUTH KOREA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 130. SOUTH KOREA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 131. TAIWAN BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 132. TAIWAN BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 133. TAIWAN BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 134. TAIWAN BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 135. TAIWAN BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 136. TAIWAN BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 137. THAILAND BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 138. THAILAND BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 139. THAILAND BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 140. THAILAND BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 141. THAILAND BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 142. THAILAND BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 143. VIETNAM BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 144. VIETNAM BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 145. VIETNAM BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 146. VIETNAM BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 147. VIETNAM BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 148. VIETNAM BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 149. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 150. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 151. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 152. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 153. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 154. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 155. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 156. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 157. DENMARK BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 158. DENMARK BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 159. DENMARK BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 160. DENMARK BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 161. DENMARK BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 162. DENMARK BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 163. EGYPT BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 164. EGYPT BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 165. EGYPT BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 166. EGYPT BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 167. EGYPT BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 168. EGYPT BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 169. FINLAND BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 170. FINLAND BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 171. FINLAND BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 172. FINLAND BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 173. FINLAND BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 174. FINLAND BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 175. FRANCE BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 176. FRANCE BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 177. FRANCE BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 178. FRANCE BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 179. FRANCE BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 180. FRANCE BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 181. GERMANY BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 182. GERMANY BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 183. GERMANY BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 184. GERMANY BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 185. GERMANY BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 186. GERMANY BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 187. ISRAEL BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 188. ISRAEL BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 189. ISRAEL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 190. ISRAEL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 191. ISRAEL BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 192. ISRAEL BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 193. ITALY BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 194. ITALY BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 195. ITALY BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 196. ITALY BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 197. ITALY BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 198. ITALY BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 199. NETHERLANDS BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 200. NETHERLANDS BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 201. NETHERLANDS BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 202. NETHERLANDS BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 203. NETHERLANDS BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 204. NETHERLANDS BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 205. NIGERIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 206. NIGERIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 207. NIGERIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 208. NIGERIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 209. NIGERIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 210. NIGERIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 211. NORWAY BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 212. NORWAY BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 213. NORWAY BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 214. NORWAY BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 215. NORWAY BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 216. NORWAY BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 217. POLAND BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 218. POLAND BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 219. POLAND BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 220. POLAND BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 221. POLAND BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 222. POLAND BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 223. QATAR BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 224. QATAR BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 225. QATAR BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 226. QATAR BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 227. QATAR BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 228. QATAR BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 229. RUSSIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 230. RUSSIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 231. RUSSIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 232. RUSSIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 233. RUSSIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 234. RUSSIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 235. SAUDI ARABIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 236. SAUDI ARABIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 237. SAUDI ARABIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 238. SAUDI ARABIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 239. SAUDI ARABIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 240. SAUDI ARABIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 241. SOUTH AFRICA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 242. SOUTH AFRICA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 243. SOUTH AFRICA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 244. SOUTH AFRICA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 245. SOUTH AFRICA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 246. SOUTH AFRICA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 247. SPAIN BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 248. SPAIN BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 249. SPAIN BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 250. SPAIN BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 251. SPAIN BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 252. SPAIN BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 253. SWEDEN BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 254. SWEDEN BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 255. SWEDEN BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 256. SWEDEN BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 257. SWEDEN BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 258. SWEDEN BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 259. SWITZERLAND BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 260. SWITZERLAND BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 261. SWITZERLAND BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 262. SWITZERLAND BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 263. SWITZERLAND BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 264. SWITZERLAND BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 265. TURKEY BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 266. TURKEY BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 267. TURKEY BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 268. TURKEY BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 269. TURKEY BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 270. TURKEY BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 271. UNITED ARAB EMIRATES BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 272. UNITED ARAB EMIRATES BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 273. UNITED ARAB EMIRATES BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 274. UNITED ARAB EMIRATES BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 275. UNITED ARAB EMIRATES BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 276. UNITED ARAB EMIRATES BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 277. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
• TABLE 278. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
• TABLE 279. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 280. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 281. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 282. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 283. BIVALIRUDIN MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 284. BIVALIRUDIN MARKET, FPNV POSITIONING MATRIX, 2023

[189 Pages Report] The Bivalirudin Market size was estimated at USD 1.23 billion in 2023 and expected to reach USD 1.31 billion in 2024, at a CAGR 6.13% to reach USD 1.87 billion by 2030.

Bivalirudin is a medication primarily used as an anticoagulant, which helps prevent blood clot formation. Bivalirudin belongs to a class of drugs known as direct thrombin inhibitors, which reduces the likelihood of clots forming in the blood vessels. This is especially important in situations where blood clots can lead to severe health issues such as heart attacks, strokes, or blockages in the arteries or veins. An increase in the global incidence of heart diseases has led to a higher need for effective treatment options, including angioplasty, where bivalirudin plays a critical role. Moreover, the significant potential for innovation in formulating bivalirudin to enhance its efficacy and reduce side effects led to more effective and safer anticoagulant options. However, the high cost of bivalirudin and related medical procedures limit its accessibility to a broader patient base. In addition, the presence of alternative anticoagulants and new drugs entering the market may challenge bivalirudin adoption among end-users. Nevertheless, an increase in healthcare infrastructure investments and spending, along with a rising burden of cardiovascular diseases, is improving the adoption of advanced drug medications. The ongoing exploration of bivalirudin in combination with other drugs is expected to open new therapeutic areas and extend the application of bivalirudin in the coming years.

Dosage Form: Significant usage of bivalirudin in injectable form during surgical procedures

The injectable form of bivalirudin is primarily used in acute settings, such as during surgical procedures or in hospitals, to provide immediate anticoagulation effects. Injection form is beneficial for rapid onset of action, which is crucial for sudden, high-risk clotting conditions. The powder form of bivalirudin offers flexibility in dosing and is often preferred for its longer shelf-life compared to premixed solutions. This form is advantageous in less urgent scenarios or for tailored dosing regimens, where precise adjustments in dosage are required to meet patients' individual needs. The injectable form is unmatched in urgency and convenience for immediate use, especially in critical care and surgical settings. Meanwhile, the powder form offers versatility and economy for situations allowing for the preparation of the drug just before use, catering to specific dosage needs, and reducing wastage.

End-Use: Emerging usage of bivalirudin in ambulatory surgical centers

Ambulatory surgical centers (ASCs) have increasingly become preferred for minor surgical procedures that don't require an overnight stay. The use of bivalirudin in ASCs primarily revolves around its minimal monitoring requirements, quick action, and shorter half-life, which makes it suitable for outpatient settings. Hospitals & clinics are the primary users of bivalirudin, given the wide range of applications in acute care settings. Hospitals and clinics use bivalirudin for more extensive and invasive cardiovascular procedures, where its quick onset and reversibility are highly beneficial. Specialty clinics, particularly those focused on cardiology, often utilize bivalirudin for patients undergoing diagnostic cardiac catheterization or other non-surgical interventions.

Regional Insights

The high prevalence of heart diseases and the advanced healthcare infrastructure stimulate the need for bivalirudin in the Americas. Customer purchasing behavior leans towards trust in clinically proven medications, with bivalirudin being preferred for its efficiency in reducing bleeding complications. European countries showcase a uniform approach towards Bivalirudin, which has been greatly influenced by European Union (EU) regulations and healthcare guidelines. The adoption varies with national healthcare systems, availability, and reimbursement policies. The growing aging population and an increase in cardiovascular diseases underscore a steady need for bivalirudin in the European Union (EU). In the Middle East and Africa, the market for Bivalirudin is emerging due to increasing investments in healthcare and collaborations with international health organizations. The Asia Pacific region represents a dynamic market for bivalirudin due to the government's push towards healthcare reform and investment in hospital infrastructure.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Bivalirudin Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Bivalirudin Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Bivalirudin Market, highlighting leading vendors and their innovative profiles. These include Apotex Inc., Aurobindo Pharma, Avenacy, Inc., Baxter International, Cayman Chemical, Cipla Limited, Dr. Reddy's Laboratories, Endo International plc, Eugia US LLC, Fresenius Kabi, Meitheal Pharmaceuticals, Inc., Merck KGaA, Midas Pharma GmbH, Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Bivalirudin Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Dosage Form
  • Injection
  • Powder

• Application
  • Angioplasty
  • Heparin-induced Thrombocytopenia
  • Percutaneous Coronary Intervention

• End-Use
  • Ambulatory Surgical Centers
  • Hospitals & Clinics
  • Specialty Clinics

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Bivalirudin Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Bivalirudin Market?

3. What are the technology trends and regulatory frameworks in the Bivalirudin Market?

4. What is the market share of the leading vendors in the Bivalirudin Market?

5. Which modes and strategic moves are suitable for entering the Bivalirudin Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing need for effective anticoagulants to treat cardiovascular disorders
    • 5.1.1.2. Growing consumer expenditure for improved drug and medications
  • 5.1.2. Restraints
    • 5.1.2.1. Expensive nature of bivalirudin compared to the alternatives
  • 5.1.3. Opportunities
    • 5.1.3.1. Emerging development of ready-to-use bivalirudin formulations
    • 5.1.3.2. Ongoing government approvals for new products
  • 5.1.4. Challenges
    • 5.1.4.1. Risks and complexities associated with use of bivalirudin
• 5.2. Market Segmentation Analysis
  • 5.2.1. Dosage Form: Significant usage of bivalirudin in injectable form during surgical procedures
  • 5.2.2. End-Use: Emerging usage of bivalirudin in ambulatory surgical centers
• 5.3. Market Disruption Analysis
• 5.4. Porter's Five Forces Analysis
  • 5.4.1. Threat of New Entrants
  • 5.4.2. Threat of Substitutes
  • 5.4.3. Bargaining Power of Customers
  • 5.4.4. Bargaining Power of Suppliers
  • 5.4.5. Industry Rivalry
• 5.5. Value Chain & Critical Path Analysis
• 5.6. Pricing Analysis
• 5.7. Technology Analysis
• 5.8. Patent Analysis
• 5.9. Trade Analysis
• 5.10. Regulatory Framework Analysis

6. Bivalirudin Market, by Dosage Form

• 6.1. Introduction
• 6.2. Injection
• 6.3. Powder

7. Bivalirudin Market, by Application

• 7.1. Introduction
• 7.2. Angioplasty
• 7.3. Heparin-induced Thrombocytopenia
• 7.4. Percutaneous Coronary Intervention

8. Bivalirudin Market, by End-Use

• 8.1. Introduction
• 8.2. Ambulatory Surgical Centers
• 8.3. Hospitals & Clinics
• 8.4. Specialty Clinics

9. Americas Bivalirudin Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Bivalirudin Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Bivalirudin Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Avenacy Introduces Generic Bivalirudin Injection, Expanding Anticoagulant Options in the U.S.
  • 12.3.2. Endo International Launches Ready-to-Use Bivalirudin Injection Enhancing Clinical Efficiency
  • 12.3.3. Endo International Announces Strategic Partnership for U.S. Distribution of Ready-to-Use Bivalirudin Injection
• 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

• 13.1. Key Company Profiles
• 13.2. Key Product Portfolio